Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pialoux

Showing results (281-290 of 421) with videos related to

Pageof 43
Sort By:
AIDS (London, England)|June 12, 2010
Factors predictive of virological failure on atazanavir in 310 HIV-infected patientsFrançois-Xavier Lescure, Jean-Marie Poirier, Jean-Luc Meynard, et al.
AIDS Research and Human Retroviruses|August 24, 2004
Use of well-defined HIV-derived epitopes to evaluate CD4(+) and CD8(+) T cell responses in patients with chronic HIV-1 infection treated with HAARTNathalie Daniel, Bénédicte Charmeteau, Sophie Grabar, et al.
European Journal of Cancer Care|October 2, 2019
Physical activity preferences before and after participation in a 6-month physical activity intervention among women with metastatic breast cancerLidia Delrieu, Jeff K Vallance, Magali Morelle, et al.
Antiviral Therapy|November 3, 2010
Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimenJade Ghosn, Giampiero Carosi, Santiago Moreno, et al.
Antiviral Therapy|December 8, 2016
Hepatic safety of maraviroc in patients with HIV-1 and hepatitis C and/or B virus: 144-week results from a randomized, placebo-controlled trialJuergen K Rockstroh, Frank Plonski, Meena Bansal, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 22, 2013
Use of first-generation HCV protease inhibitors in patients coinfected by HIV and HCV genotype 1Dominique Salmon-Ceron, Cédric Arvieux, Marc Bourlière, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 14, 2016
Longitudinal Changes Over 10 Years in Free Testosterone Among HIV-Infected and HIV-Uninfected MenLaurence Slama, Lisa P Jacobson, Xiuhong Li, et al.
The Journal of Antimicrobial Chemotherapy|June 21, 2019
First year of pre-exposure prophylaxis implementation in France with daily or on-demand tenofovir disoproxil fumarate/emtricitabineM Siguier, R Mera, G Pialoux, et al.
AIDS and Behavior|May 1, 2020
Coverage of Sex Acts by Event-Driven Pre-exposure Prophylaxis: A Sub-Study of the ANRS IPERGAY TrialRebecca Bauer, Emmanuelle Netzer, Claire Pintado, et al.
HIV Medicine|July 25, 2008
Viral efficacy maintained and safety parameters improved with a reduced dose of stavudine: a pilot studyH Ait-Mohand, M Bonmarchand, M Guiguet, et al.
Pageof 43

Showing results (281-290 of 421) with videos related to

Sort By:
Pageof 43
AIDS (London, England)|June 12, 2010
Factors predictive of virological failure on atazanavir in 310 HIV-infected patientsFrançois-Xavier Lescure, Jean-Marie Poirier, Jean-Luc Meynard, et al.
AIDS Research and Human Retroviruses|August 24, 2004
Use of well-defined HIV-derived epitopes to evaluate CD4(+) and CD8(+) T cell responses in patients with chronic HIV-1 infection treated with HAARTNathalie Daniel, Bénédicte Charmeteau, Sophie Grabar, et al.
European Journal of Cancer Care|October 2, 2019
Physical activity preferences before and after participation in a 6-month physical activity intervention among women with metastatic breast cancerLidia Delrieu, Jeff K Vallance, Magali Morelle, et al.
Antiviral Therapy|November 3, 2010
Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimenJade Ghosn, Giampiero Carosi, Santiago Moreno, et al.
Antiviral Therapy|December 8, 2016
Hepatic safety of maraviroc in patients with HIV-1 and hepatitis C and/or B virus: 144-week results from a randomized, placebo-controlled trialJuergen K Rockstroh, Frank Plonski, Meena Bansal, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 22, 2013
Use of first-generation HCV protease inhibitors in patients coinfected by HIV and HCV genotype 1Dominique Salmon-Ceron, Cédric Arvieux, Marc Bourlière, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 14, 2016
Longitudinal Changes Over 10 Years in Free Testosterone Among HIV-Infected and HIV-Uninfected MenLaurence Slama, Lisa P Jacobson, Xiuhong Li, et al.
The Journal of Antimicrobial Chemotherapy|June 21, 2019
First year of pre-exposure prophylaxis implementation in France with daily or on-demand tenofovir disoproxil fumarate/emtricitabineM Siguier, R Mera, G Pialoux, et al.
AIDS and Behavior|May 1, 2020
Coverage of Sex Acts by Event-Driven Pre-exposure Prophylaxis: A Sub-Study of the ANRS IPERGAY TrialRebecca Bauer, Emmanuelle Netzer, Claire Pintado, et al.
HIV Medicine|July 25, 2008
Viral efficacy maintained and safety parameters improved with a reduced dose of stavudine: a pilot studyH Ait-Mohand, M Bonmarchand, M Guiguet, et al.
Pageof 43